COMPANY OVERVIEW

Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.

---

LOCATION

Stockholm, , Sweden

---

THERAPEUTIC AREAS

Hematology

---

WEBSITE

https://www.modustx.com/

---

CAREER WEBSITE

https://www.modustx.com/contact/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Sep 27, 2022

Karolinska Development’s portfolio company Modus Therapeutics has completed recruitment in a clinical phase 1b study of sevuparin

Sep 27, 2022

Karolinska Developments portföljbolag Modus Therapeutics har slutfört rekryteringen till en klinisk fas 1b-studie med sevuparin

Sep 2, 2022

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Dec 1, 2021

Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin

Jul 15, 2021

Karolinska Developments portföljbolag Modus Therapeutics tillförs SEK 33 miljoner efter en övertecknad emission och förbereder nu inför börsnotering

For More Press Releases

---